NORTH AMERICAN BUSINESS
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
NORTH AMERICAN BUSINESS
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
NORTH AMERICAN BUSINESS
No Result
View All Result
Home ALL Healthcare

AstraZeneca and Regeneron to research, develop and commercialise new small molecule medicines for obesity

by Emma Jones
July 28, 2021
A A

Novel small molecule drug candidates will target GPR75 to potentially address obesity and related co-morbidities
 

AstraZeneca has entered into a collaboration with Regeneron to research, develop and commercialise small molecule compounds directed against the GPR75 target with the potential to treat obesity and related co-morbidities. The companies will evenly split research and development costs and share equally in any future potential profits.

As published in Science, the new target was found by sequencing nearly 650,000 people and identifying individuals with rare protective mutations. Individuals with at least one inactive copy of the GPR75 gene had lower body mass index (BMI) and, on average, tended to weigh about 12 pounds less and faced a 54% lower risk of obesity than those without the mutation.1 Strong associations were also seen with improvements in diabetes parameters, including glucose lowering.1 Obesity and insulin resistance are key drivers in the development of type-2 diabetes and often lead to cardiorenal complications, as well as liver disease.

Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca, said: “We are pleased to announce this important collaboration with Regeneron to identify small molecule modulators against GPR75, a newly identified target with genetic validation in metabolic disorders. Obesity and insulin resistance remain key drivers in the development of type-2 diabetes and areas of significant unmet medical need.”

George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of Regeneron, said: “The next era of drug development is being fuelled by important genetic findings that direct drug developers on how to deploy our toolkit of biologics, small molecules and gene editing technologies. As experts on genetics and human biology, Regeneron is excited to join forces with the chemistry and small molecule leaders at AstraZeneca, as we seek to develop new medicines tackling the harmful and costly obesity epidemic.”

Tags: < Partnership
ShareTweetShareSend

Related Industries

Healthcare

Bayer Announces Changes to U.S. Country Leadership Team

June 9, 2023
Healthcare

Cardinal Health announces the merger of its Outcomes™ business into Transaction Data Systems and related partnership

June 6, 2023
Healthcare

Medtronic names Ken Washington new Chief Technology and Innovation Officer

June 2, 2023
Healthcare

BD Names Laura Boros President of Pharmaceutical Systems

June 2, 2023
Healthcare

Medtronic to acquire wearable insulin patch maker EOFlow

May 26, 2023
Healthcare

Thermo Fisher Scientific Releases 2022 Corporate Social Responsibility Report

May 18, 2023

Gap Inc. Releases 2022 ESG Report, Sharing Progress On Sustainability And Inclusion

May 10, 2023

...

Toshiba Named a Major Player in the IDC MarketScape “Worldwide Retail Commerce Platform Software Providers 2023 Vendor Assessment”

May 17, 2023

...

3M and Svante announce joint development agreement to develop and produce carbon dioxide removal products

May 17, 2023

...

Dow and New Energy Blue to develop renewable plastic materials from corn residue.

Dow and New Energy Blue announce collaboration to develop renewable plastic materials from corn residue

May 26, 2023

...

Apple’s Worldwide Developers Conference to kick off June 5, 2023, with keynote address

May 24, 2023

...

MSC’s largest cruise ship, World Europa (World Class Series), is equipped with GE Power Conversion’s in-board propulsion system

May 12, 2023

...

IBM Unveils the Watsonx Platform to Power Next-Generation Foundation Models for Business

May 10, 2023

...

Amgen Responds to Ftc Action RE: Proposed Acquisition Of Horizon Therapeutics

May 17, 2023

...

GM Furthers Flint Commitment with $1B+ Manufacturing Investment

June 6, 2023

...

NORTH AMERICAN BUSINESS (www.na-biz.com) is a leading source of business and corporate news, information, industry trends, market updates and insights across a broad spectrum of industries in North America and worldwide.

MENU

  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

CONTACT US

EDITORIAL:     editor#na-biz.com

PARTNERSHIP:     biz#na-biz.com

HUMAN RESOURCE:     hr#na-biz.com

* (replace # with @)

  • Official Site

Copyright © NA-BIZ.COM All rights reserved.

No Result
View All Result
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

Copyright © NA-BIZ.COM All rights reserved.